Eskazan T, Saribas S, Kocazeybek B. Prognostic value of the triglyceride-glucose index in gastric cancer. World J Gastroenterol 2025; 31(17): 104651 [DOI: 10.3748/wjg.v31.i17.104651]
Corresponding Author of This Article
Bekir Kocazeybek, Professor, Department of Medical Microbiology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Kocamustafapaşa St No. 53, Istanbul 34098, Türkiye. bzeybek@istanbul.edu.tr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2025; 31(17): 104651 Published online May 7, 2025. doi: 10.3748/wjg.v31.i17.104651
Prognostic value of the triglyceride-glucose index in gastric cancer
Tugce Eskazan, Suat Saribas, Bekir Kocazeybek
Tugce Eskazan, Department of Internal Medicine, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul 34640, Türkiye
Suat Saribas, Bekir Kocazeybek, Department of Medical Microbiology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul 34098, Türkiye
Co-first authors: Tugce Eskazan and Suat Saribas.
Author contributions: Eskazan T and Saribas S contribute equally to this study as co-first authors; Eskazan T, Saribas S, and Kocazeybek B contributed to this paper; Kocazeybek B designed the overall concept; Eskazan T contributed to the writing, discussion and design of the manuscript; Saribas S contributed to the editing the manuscript, illustrations, and review of literature.
Conflict-of-interest statement: There is no conflict of interest related to this letter to the editor.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bekir Kocazeybek, Professor, Department of Medical Microbiology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Kocamustafapaşa St No. 53, Istanbul 34098, Türkiye. bzeybek@istanbul.edu.tr
Received: December 27, 2024 Revised: March 4, 2025 Accepted: March 21, 2025 Published online: May 7, 2025 Processing time: 123 Days and 21.2 Hours
Abstract
Advanced gastric cancer (GC) remains a high-mortality malignancy despite progress in diagnosis and treatment, including immunotherapy. Reliable prognostic markers are essential for better patient stratification. The triglyceride-glucose (TyG) index, a marker of insulin resistance, has shown promise in various cancers, but its role in GC remains unclear. Yao et al investigated its prognostic value in 300 patients with advanced GC receiving immunotherapy and chemotherapy. Their model, which integrates the TyG index, programmed death-ligand 1 expression, and Eastern Cooperative Oncology Group performance status, underscores the impact of metabolic dysfunction on immune response and treatment efficacy. This letter examines the TyG index’s potential as a prognostic tool in GC and its implications for treatment strategies guided by metabolic and immune factors, as demonstrated in Yao et al research.
Core Tip: Gastric cancer (GC) remains a high-mortality malignancy despite advances in diagnostics and treatments. Histopathological and biochemical markers that predict prognosis are crucial for treatment planning and assessing mortality and morbidity risk. Recent studies highlight the prognostic value of the triglyceride-glucose ratio (an indirect indicator of insulin resistance) in various cancer types. However, a deeper understanding of its role in predicting the immunotherapy response in GC is critically needed.
